{"id":"droxicam","rwe":[{"pmid":"41210757","year":"2025","title":"Targeting Ubiquitin-Specific Protease 7 (USP7): A Pharmacophore-Guided Drug Repurposing and Physics-Based Molecular Simulation Study.","finding":"","journal":"ACS omega","studyType":"Clinical Study"},{"pmid":"33455779","year":"2021","title":"Ultrasensitive and simultaneous detection of 6 nonsteroidal anti-inflammatory drugs by colloidal gold strip sensor.","finding":"","journal":"Journal of dairy science","studyType":"Clinical Study"},{"pmid":"23656309","year":"2013","title":"Computational nanochemistry report on the oxicams--conceptual DFT indices and chemical reactivity.","finding":"","journal":"The journal of physical chemistry. B","studyType":"Clinical Study"},{"pmid":"22946893","year":"2012","title":"Anti-inflammatory drugs and prediction of new structures by comparative analysis.","finding":"","journal":"Anti-inflammatory & anti-allergy agents in medicinal chemistry","studyType":"Clinical Study"},{"pmid":"16867024","year":"2006","title":"Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems.","finding":"","journal":"Fundamental & clinical pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"droxicam","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"M01AC04","category":"atc"},{"label":"Active","category":"status"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"droxar","offLabel":[],"synonyms":["droxicam","dobenam","droxar","ombolan"],"timeline":[],"approvals":[],"brandName":"Droxar","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"droxicam","explanation":"Think of prostaglandins like messengers that tell your body to feel pain and become inflamed. By blocking these messengers, Droxar helps to reduce pain and inflammation. This can be especially helpful for people with conditions like arthritis or other inflammatory diseases.","oneSentence":"Droxar works by blocking enzymes that produce prostaglandins, which are hormone-like substances that cause pain and inflammation.","technicalDetail":"Droxar, as a droxicam, is a competitive inhibitor of cyclooxygenase enzymes (COX-1 and COX-2), which are responsible for converting arachidonic acid into prostaglandins. By inhibiting these enzymes, Droxar reduces the production of prostaglandins, leading to decreased pain and inflammation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/970","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DROXICAM","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:49:54.437359","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:49:25.199854+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"piroxicam","drugSlug":"piroxicam","fdaApproval":"1982-04-06","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"meloxicam","drugSlug":"meloxicam","fdaApproval":"2000-04-13","patentExpiry":"May 26, 2030","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"droxicam","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"piroxicam","brandName":"piroxicam","genericName":"piroxicam","approvalYear":"1982","relationship":"same-class"},{"drugId":"meloxicam","brandName":"meloxicam","genericName":"meloxicam","approvalYear":"2000","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005989","UNII":"F24ADO1E2D","CHEBI":"CHEBI:76133","INN_ID":"5616","RXNORM":"23687","UMLSCUI":"C0058765","ChEMBL_ID":"CHEMBL1213420","KEGG_DRUG":"D07267","DRUGBANK_ID":"DB09215","PUBCHEM_CID":"65679","MESH_SUPPLEMENTAL_RECORD_UI":"C049073"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":49,"therapeuticAreas":["Pain"],"atcClassification":{"source":"DrugCentral","atcCode":"M01AC04","allCodes":["M01AC04"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Nov 4","pmid":"41210757","title":"Targeting Ubiquitin-Specific Protease 7 (USP7): A Pharmacophore-Guided Drug Repurposing and Physics-Based Molecular Simulation Study.","journal":"ACS omega"},{"date":"2021 Mar","pmid":"33455779","title":"Ultrasensitive and simultaneous detection of 6 nonsteroidal anti-inflammatory drugs by colloidal gold strip sensor.","journal":"Journal of dairy science"},{"date":"2013 May 30","pmid":"23656309","title":"Computational nanochemistry report on the oxicams--conceptual DFT indices and chemical reactivity.","journal":"The journal of physical chemistry. B"},{"date":"2012","pmid":"22946893","title":"Anti-inflammatory drugs and prediction of new structures by comparative analysis.","journal":"Anti-inflammatory & anti-allergy agents in medicinal chemistry"},{"date":"2006 Aug","pmid":"16867024","title":"Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems.","journal":"Fundamental & clinical pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Droxar (DROXICAM) is a small molecule drug in the droxicam class, but specific details about its development, approval status, and commercial status are not available. As a droxicam, it is likely a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes. However, without further information, it is unclear what specific indications Droxar is approved for or its pharmacokinetic properties. Further research is needed to determine its commercial status and key safety considerations. As a result, Droxar's clinical use and potential risks are currently unknown.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:49:25.199854+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}